**TITLE**

# Utilization of non-invasive urine sampling with multiplex PCR to enhance cervical cancer screening in developing countries: a cross-sectional diagnostic accuracy study

**AUTHORS**

Novia Syari Intan[1], Revata Utama[1,*], Dewi Wulandari[2], Reiva Wisdharilla[2], Shafira Mutia Khanza[1], Muhammad Rifki Ramadhan[1], Indah Suci Widyahening[3], Neni Nurainy[4], Rini Mulia Sari[5], Andrijono[6]

**AFFILIATIONS**

[1] Nusantics, PT. Riset Nusantara Genetika, Jakarta, Indonesia

[2] Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

[3] Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

[4] Translational Development of Life Science Product Division, PT Bio Farma, Bandung, Indonesia

[5] Surveillance and Clinical Research Division, PT Bio Farma, Bandung, Indonesia

[6] Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

**CORRESPONDING AUTHOR**

*Revata Utama: revata@nusantics.com

**ABSTRACT**

**Background**

More than half of the predicted cervical cancer deaths are expected to be prevented with improved screening and management strategies. However, the conventional cervical screening procedure is considered as uncomfortable and embarrassing for most women in developing countries, such as Indonesia, leading to a low participation rate of screening. In response, we assessed the performance of the newly developed hrHPV ReadyMix qPCR Kit to detect high-risk human papillomavirus (HPV) in urine samples and conduct simultaneous genotyping of HPV16, HPV18, and HPV52.

**Methods**

We enrolled women aged 20-50 years from three cities in Indonesia, specifically Jakarta, Bandung, and Semarang. Participants were instructed to provide self-collected first-void urine samples, followed by a physician-assisted cervical swab sample collection. Nucleic acids were then extracted and tested for HPV with Roche cobas® 6800 HPV and hrHPV ReadyMix qPCR kit. Next generation-sequencing (NGS) was employed in cases of discrepant results. hrHPV ReadyMix diagnostics accuracy were assessed against Roche cobas® 6800 HPV as a reference test and the utility of urine samples as an alternative sampling method were compared to the standard cervical swab samples.

**Results**

876 paired samples were analysed for HPV detection. The sensitivity of HPV detection in cervical swabs using hrHPV ReadyMix qPCR Kit reached 96.55% and the specificity reached 99.87%. Despite having a tendency to produce higher Ct value in high-risk HPV detection, urine samples produced a high sensitivity at 80.88% and a specificity of 100.00% when compared to cervical swabs. Our developed method enables population-based high-risk HPV

analysis with 6.62% HPV prevalence based on cervical swabs and 6.28% HPV prevalence based on urine samples. Urine samples, tested with the hrHPV ReadyMix qPCR Kit, exhibited comparable HPV positivity rate to cervical swabs and similar genotyping capability of HPV16 and HPV18 as the Roche cobas® 6800 HPV system.

**Conclusions**

We demonstrated that self-collected urine samples can be an alternative specimen to detect HPV infection with a diagnostic accuracy of 98.48%. This study highlights the potential of the hrHPV ReadyMix qPCR Kit in improving cervical cancer screening and provides valuable insights for future interventions.

**KEYWORDS**

Cervical cancer screening, high-risk human papillomavirus, HPV, HPV-DNA test, HPV molecular test, in vitro diagnosis, urine specimens, polymerase chain reaction, qPCR, self-collected specimen.

## BACKGROUND

Cervical cancer is the fourth most prevalent type of cancer among women, with approximately 604,127 cases and 341,831 fatalities worldwide in 2020.[1] The distribution of cervical cancer cases varies across the globe, with developing countries accounting for 85% of the mortality[2]. In Indonesia, it is estimated that there are approximately 36,633 cases and 21,003 deaths related to cervical cancer per year.[3] However, the disease is preventable and treatable if detected early. As over 99% of precancerous lesions (cervical dysplasia) and cervical carcinomas are caused by high-risk HPV infection,[4] detection of high-risk HPV as the etiologic factor of cervical cancer cases has emerged as a primary early-screening method due

73 to its greater sensitivity than the Pap test for detecting precancerous lesions of the cervix.[5,6]
74 It also offers the advantage of extended screening intervals from once every 3 years to once
75 every 5 years as well as eliminating the need for skilled cytopathologists to interpret the
76 results[4,5].
77
78 However, implementation of HPV-based diagnostics in emerging countries faces a multitude
79 of challenges, such as the high costs of screening tests, shortages of the appropriate
80 diagnostic kits, and a lower than 10% screening participation rate in such countries, such as
81 Myanmar and Indonesia.[7,8] To increase the low participation rates, a self-sampling approach
82 combining detection of HPV from urine samples with the utilization of the currently available
83 infrastructure of quantitative polymerase chain reaction (qPCR) instruments was developed
84 as an alternative to cervical swab-based HPV screening method. The use of urine samples
85 offers several advantages, such as more privacy and less embarrassment in the sample
86 collection process, reduced discomfort and pain, as well as ease of use. Furthermore, previous
87 studies have shown that urine samples have a promising accuracy for HPV detection.[9-11] To
88 address those needs, the hrHPV ReadyMix qPCR Kit (ReadyMix) has been developed to detect
89 14 high-risk HPV types with the capability to genotype HPV52, HPV16, and HPV18 in both
90 cervical swabs and urine samples. HPV16 and HPV18 contribute to about 70% of all cervical
91 cancer cases. Alongside HPV52, they constituted the highest prevalence in Southeast Asia
92 countries.[4,12] Our study aimed to evaluate the performance of HPV detection in urine samples
93 as compared to standard cervical swabs using the ReadyMix, which was assessed for
94 performance against the Roche cobas® 6800 HPV system. The insights gained from this study
95 will contribute to the effort to achieve effective screening measures, not only in Indonesia
96 but also in other countries with similar settings, thus reducing the burden of the disease.

97

98 **MATERIALS AND METHODS**

99 **Study Design and Population**

100 This cross-sectional diagnostic test accuracy study was conducted based on HPV detection
101 results from a study population comprising sexually active women aged 20 to 50 years
102 residing in three major Indonesian cities: Jakarta, Bandung, and Semarang. The study focused
103 on women who sought healthcare services for general medical check-ups, Pap smears, or
104 visual inspection with acetic acid (VIA) test and willingly agreed to take part in the study. The
105 subjects were asked to provide urine and cervical swab samples. Pregnant women, those
106 currently menstruating, and individuals who had already received the HPV vaccine were
107 excluded from the study. This recruitment was conducted between August 2022 and January
108 2023.

109

110 **Specimen Collection**

111 The participants were first instructed to collect their first-void urine, collected at any time of
112 the day, in a urine container. The cervical swab was then taken with a physician's assistance
113 using a cervical brush and preserved in PreservCyt ® Solution (Hologic, Belgium). Both samples
114 were kept at a temperature between 2-8°C and sent to the Clinical Pathology Department
115 laboratory at the Cipto Mangunkusumo National Hospital for further analysis.

116

117 **DNA Extraction**

118 The DNA was extracted from both urine and cervical swab samples using Zybio Nucleic Acid
119 Extraction Kit (Zybio Inc., China) as per the manufacturer's instructions for ReadyMix. The
120 integrity of the extracted DNA was assessed by detecting the β-globin gene, later in the qPCR

121 stage. The samples were simultaneously run in cobas®6800 HPV (Roche, Switzerland) where
122 extraction and amplification are integrated in automatic system.
123
124 **HPV qPCR and Genotyping Protocol**
125 The purified DNA was subjected to qPCR assays using ReadyMix performed in the CFX96™
126 System (Bio-Rad Lab, CA, USA) and using cobas® 6800 HPV (Roche, Switzerland) (cobas)
127 directly in the system. ReadyMix was developed by Nusantics and commercialized under the
128 name of PathoScan (Nusantics, Indonesia) and CerviScan (PT Biofarma, Indonesia). hrHPV
129 ReadyMix qPCR Kit targets the E6-E7 region to identify 14 high-risk HPV types while
130 concurrently differentiating between HPV16, HPV18, and HPV52. Other HPV types targeted
131 include HPV 31, 33, 35, 39, 45, 51, 56, 58, 59, 66, and 68, collectively detected in one
132 fluorescence channel. Both tests detect human β-globin gene as an internal control (IC) to
133 monitor the success of the extraction and qPCR procedure. cobas assay was performed
134 according to the manufacturer's instructions. ReadyMix reagent was pre-mixed in a single
135 tube and thus can be directly aliquoted to qPCR well in a volume of 15 µL for a 20 µL qPCR
136 reaction. This kit was then also used as per manufacturer recommendation, with PCR thermal
137 cycles consisting of 95°C initial denaturation for 2 minutes and 45 cycles of 1-second
138 denaturation at 95°C and 10 seconds annealing/extension at 60°C. The cutoff Ct value for a
139 sample to be considered positive is 40.
140 In samples that show discordant results between the two testing methods or between
141 different sample types, the presence of HPV DNA is confirmed using the amplicon sequencing
142 method utilizing NGS technology. DNA libraries were amplified by PCR, prepared using
143 Nextera XT index kit v2 (Illumina, CA, USA), and purified using AmPure XP beads (Beckman-
144 Coulter, CA, USA). Paired-end (2x150 bp) sequencing was performed using the Illumina Miseq

145 Micro v2 reagent kit (Illumina, CA, USA) on the MiSeq platform. The sequencing primers used
146 have been previously validated through alignment between the sequencing results of
147 synthetic genes and their corresponding references. Reads were demultiplexed based on
148 their index, resulting in a pair of forward and reverse fastq file for each sample. The
149 downstream data analysis was performed using QIIME2 platform.[13] Primer sequences were
150 trimmed and reads were filtered based on their length using cutadapt,[14] with a cutoff length
151 of 20. Forward and reverse reads were merged using vsearch,[15] allowing a maximum of 5
152 mismatches. In this step, a minimum merged read length of 30 for E6-E7 was enforced.
153 Merged reads were quality-filtered based on their Q score with a cutoff value of 30 prior to
154 dereplication. Reads were clustered *de novo* to produce operational taxonomic units with
155 99% similarity. Chimera sequences were filtered out using vsearch utility uchime-denovo. The
156 resulting sequences were classified into either of HPV types by mapping them to HPV
157 reference sequences that are obtained from Papillomavirus Episteme (PaVE)
158 (https://pave.niaid.nih.gov/). The mapping was performed using BLASTn with a minimum of
159 90% identity and a minimum word size of 20. [16]
160
161 **Statistical analysis**
162 The data were assessed for normality using the Shapiro-Wilk test. Categorical variables were
163 presented as percentages. For measures of central tendency, the mean ± standard deviation
164 (SD) was applied to normally distributed data, while the median (interquartile range; IQR) was
165 employed for non-normally distributed data. The study calculated the sensitivity, specificity,
166 positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy to
167 evaluate the diagnostic performance. Cohen's Kappa coefficient ($\kappa$) was used to determine
168 concordance between compared tests or samples.[17] The Wilcoxon matched-pairs signed rank

169 test was performed to compare qPCR Ct values between urine and cervical swabs. All
170 statistical analyses were executed using GraphPad statistical software version 10.0.2
171 (GraphPad San Diego, CA, USA).
172
173 **RESULTS**
174 **hrHPV ReadyMix qPCR Kit demonstrates high sensitivity and specificity in the detection of**
175 **high-risk HPV**
176 A total of 876 subjects from three sampling sites were included in this study. The mean age
177 of the subjects was 37.23±7.28 years. All subjects were tested for HPV by ReadyMix and
178 cobas. HPV detection in this study specifically refers to high-risk HPV detection. ReadyMix's
179 technical performance has been previously characterized based on linearity assay and limit of
180 detection (LoD) which yielded satisfactory results (Additional File 1: Supplementary Fig. S1,
181 S2). Among the 876 cervical swab and urine samples tested with cobas, there were 24 cervical
182 swab samples (2.74%) and 206 urine samples (23.52%) that yielded invalid results (Table 1).
183 On the other hand, ReadyMix produced a smaller number of invalid results, with only 2
184 cervical swab samples (0.23%) and 19 urine samples (2.17%) being invalid (Table 1).
185
186 Table 1. Summary of Test Participation and Validity in Study Subjects

| **Results** | **ReadyMix** | | **cobas** | |
|---|---|---|---|---|
| | **Cervical Swab** | **Urine** | **Cervical Swab** | **Urine** |
| Total subjects | 876 | 876 | 876 | 876 |
| Subject with complete test result | 874 | 857 | 852 | 670 |

| Invalid | 2 | 19 | 24 | 206 |
|---|---|---|---|---|
| Invalid Rate | 0.23% | 2.17% | 2.74% | 23.52% |

187

188 We first sought to determine the diagnostic performance of ReadyMix in HPV detection using

189 the cervical swab as a standard method. The accuracy was excellent with a sensitivity of

190 96.15% (95% CI: 87.02-99.32%) and a specificity of 99.13% (95% CI: 98.2-99.58) (Table 2).

191

192 Table 2. HPV detection in the cervical swab using ReadyMix versus cobas

| **Cervical Swab ReadyMix** | **Cervical Swab cobas** | | | **k-coefficient** |
|---|---|---|---|---|
| | **Positive** | **Negative** | **Total** | |
| Positive | 50 | 7 | 57 | 0.91 |
| Negative | 2 | 793 | 795 | |
| Total | 52 | 800 | 852 | |
| **Effect size** | **Value (%)** | **95% CI (%)** | | |
| Sensitivity | 96.15 | 87.02 - 99.32 | | |
| Specificity | 99.13 | 98.2 - 99.58 | | |
| Positive Predictive Value | 87.72 | 76.75 - 93.92 | | |
| Negative Predictive Value | 99.75 | 99.09 - 99.96 | | |
| Accuracy | 98.94 | 98.00 - 99.44 | | |

193

194 Upon observing samples with discordant results, we found that 6 out of 7 false-positives

195 results were confirmed true-positives by the NGS results (Additional File 1: Supplementary

196 Table S1). To obtain a clearer performance report of this assay, we then incorporate NGS data,
197 which resulted in 96.55% (95% CI: 88.27-99.39%) sensitivity and 99.87% (95% CI: 99.29-
198 99.99%) specificity (Table 3). Cohen's Kappa analysis (0.97) indicated an almost perfect
199 agreement between the compared methods.
200
201 Table 3. HPV detection in the cervical swab using ReadyMix versus cobas and NGS

| **Cervical Swab ReadyMix** | **Cervical Swab cobas & NGS** | | | **k-coefficient** |
|---|---|---|---|---|
| | **Positive** | **Negative** | **Total** | |
| Positive | 56 | 1 | 57 | 0.97 |
| Negative | 2 | 793 | 795 | |
| Total | 58 | 794 | 852 | |
| **Effect size** | **Value (%)** | **95% CI (%)** | | |
| Sensitivity | 96.55 | 88.27 - 99.39 | | |
| Specificity | 99.87 | 99.29 - 99.99 | | |
| Positive Predictive Value | 98.25 | 90.71 - 99.91 | | |
| Negative Predictive Value | 99.75 | 99.09 - 99.96 | | |
| Accuracy | 99.65 | 98.97 - 99.90 | | |

202
203 **Urine samples exhibit an excellent agreement with cervical swabs in HPV detection**
204 To validate the use of urine sample for HPV detection, we compared its performance with a
205 well-established cervical swab sample. The NGS-corrected data were used to analyse the
206 ReadyMix's performance. The NGS results were attached in supplementary data (Additional
207 File 1: Supplementary Table S1; Supplementary Fig.S3). We found an almost perfect

208 agreement (κ: 0.89) between cervical swabs and urine with a sensitivity of 80.88% (95% CI:
209 69.99-88.47%) and 100% (95% CI: 99.51-100%) specificity (Table 4). This result demonstrates
210 enhanced accuracy in urine HPV detection on ReadyMix as compared to cobas (Additional File
211 1: Supplementary Table S2).
212
213 Table 4. HPV detection using ReadyMix in urine samples versus cervical swabs and NGS

| **Urine ReadyMix** | **Cervical Swab ReadyMix & NGS** | | | **k-coefficient** |
|---|---|---|---|---|
| | **Positive** | **Negative** | **Total** | |
| Positive | 55 | 0 | 55 | 0.89 |
| Negative | 13 | 787 | 800 | |
| Total | 68 | 787 | 855 | |
| **Effect size** | **Value (%)** | **95% CI (%)** | | |
| Sensitivity | 80.88 | 69.99 - 88.47 | | |
| Specificity | 100.00 | 99.51 - 100 | | |
| Positive Predictive Value | 100.00 | 93.47 - 100 | | |
| Negative Predictive Value | 98.38 | 97.24 - 99.05 | | |
| Accuracy | 98.48 | 97.42 - 99.11 | | |

214
215 **Urine samples show a high sensitivity across low, moderate, and high cervical swab Ct value**
216 **group**
217 Upon analyzing the HPV's Ct values of paired cervical swab and urine samples, a significant
218 difference was observed between the two samples based on Wilcoxon matched-pairs signed
219 rank test (p-value <0.0001) (Fig. 1A). The cervical swabs exhibited a lower median HPV's Ct

220 value (31.89 (8.41)) as compared to urine samples (35.69 (3.85)), resulting in 3.80 of median
221 difference. The Ct value of IC detection also showed a similar pattern whereby cervical swabs
222 produced a lower median (26.685 (3.82)) as compared to urine samples (30.69 (3.18)) (Fig.
223 1B).
224
225 The HPV's Ct value median differences of the two samples follow a pattern whereby the
226 difference tends to be lower as the Ct values get higher. The low Ct group (Ct<30) of cervical
227 swab samples had median Ct value of 26.08 (3.51) with the corresponding urine samples
228 having a median Ct value of 34.11 (6.24) (Fig. 1C). The medium Ct group (Ct 30-35) had a
229 median Ct value of 31.63 (1.53) in cervical swabs while the corresponding urine samples have
230 a median Ct value of 36.26 (3.36) (Fig. 1C). The high Ct group (Ct>35), had cervical swab's
231 median Ct value of 36.76 (2.66) with the paired urine samples having a median of 36.39 (3.04)
232 (Fig. 1C). Thus, the median difference between urine and cervical swabs for low, medium, and
233 high Ct values were 8.03, 4.63, and 0.37, respectively. Despite the wider median gap at a
234 lower Ct value and a tendency to produce higher Ct, the sensitivity of urine samples is
235 maintained at a high level across all Ct groups, ranging from 80.88% positive percentage
236 agreement when considering all samples to 99.44% positive percentage agreement when
237 calculating for samples with Ct < 30 (Fig. 1D).
238




Figure 1. The Ct value of HPV detection in cervical swabs and urine samples was significantly different (Wilcoxon matched-pairs signed rank test, p-value: <0.0001) with cervical swabs having a tendency to produce a lower Ct value (A). This finding was supported by a similar pattern of the Ct value of IC detection (B). However, the Ct value differences between cervical swabs and urine samples decrease as the sample's Ct value increases (C), and the sensitivity of HPV detection in urine samples is maintained at a high level across all Ct values.

**hrHPV ReadyMix qPCR Kit and cobas® 6800 HPV produced a comparable HPV prevalence pattern across different age groups and locations**

A total of 876 subjects participated in this study consisting of 157 subjects within the age group 20-29 (17.92%), 346 subjects within the age group 30-39 (39.50%), and 373 subjects within the age group 40-50 (42.58%). As many as 385 subjects were from Jakarta (43.95%), 355 subjects from Bandung (40.53%), and 136 subjects from Semarang (15.53%) (Additional File1: Supplementary Table S3).




Figure 2. ReadyMix identified a higher HPV prevalence, as supported by NGS results, indicating increased sensitivity (A); This result slightly affected the prevalence distribution across different age groups, where ReadyMix found a higher prevalence in the age group 40-50 compared to 30-39, while cobas found the opposite (B). However, the two tests showed a similar trend, especially in discovering

260 the age group 20-29 to have the lowest prevalence among all groups. On the other hand, the
261 prevalence distributions based on locations observed by ReadyMix and cobas were less affected,
262 resulting in a similar pattern in both cervical swabs and urine samples (C).
263
264 The HPV prevalence of the study population was slightly higher when tested by ReadyMix as
265 compared to cobas (Fig. 2A). ReadyMix showed an HPV prevalence of 6.62% and 6.28%, based
266 on cervical swabs and urine respectively, while cobas showed an HPV prevalence of 5.94%
267 and 5.82%, based on cervical swabs and urine respectively. As previously described, most of
268 the additional positive samples were proven to be true-positives by NGS, suggesting the
269 superior performance of the ReadyMix. However, we found a similar HPV prevalence shown
270 by the two tests across different age groups and different locations.
271
272 The 20-29 age group had the lowest HPV prevalence according to both tests based on cervical
273 swabs (ReadyMix: 3.82%; cobas: 4.46%) and urine (ReadyMix: 3.82%; cobas: 3.18%) (Fig. 2B).
274 ReadyMix indicated a marginally higher prevalence in the age group of 40-50 (Cervical swab:
275 7.24%, Urine: 7.51%) compared to the 30-39 group (Cervical swab: 7.23%, Urine: 6.07%).
276 Conversely, cobas showed a higher prevalence in the 30-39 group (Cervical swab: 6.65%,
277 Urine: 6.94%) compared to the 40-50 group (Cervical swab: 5.90%, Urine: 5.90%) (Fig. 2B).
278 This contrasting finding mostly result from several (5 cervical swabs and 5 urine) samples from
279 the 40-50 group that were tested negative by cobas but were found to be HPV-positive by
280 ReadyMix and confirmed by NGS (Additional File 1: Supplementary Table S1).
281
282 Comparing the prevalence across different locations, both tests show that Semarang had the
283 highest HPV prevalence based on cervical swab samples (ReadyMix: 8.89%; cobas: 7.35%),

284 followed by Bandung (ReadyMix: 6.48%; cobas: 5.92%), while Jakarta presented with the
285 lowest HPV prevalence (ReadyMix: 5.97%; cobas: 5.45%) (Fig. 2C). This similar pattern was
286 also observed in urine samples with Semarang's HPV prevalence of 9.56% and 8.09% by
287 ReadyMix and cobas respectively, followed by Bandung (ReadyMix: 6.20%; cobas: 5.63%)
288 while Jakarta continued to have the lowest prevalence among the three locations (ReadyMix:
289 5.19%; cobas: 5.19%).
290
291 **Similar HPV positive percentage proportion is observed in both urine samples and cervical**
292 **swabs**
293 Besides the similar HPV prevalence, the pattern of HPV proportion in urine samples was also
294 proportional to that of cervical swabs, with HPV Others having the highest proportion
295 (Cervical swab: 50.00%; Urine: 45.45%), followed by HPV52 (Cervical swab: 17.24%; Urine:
296 21.82%), HPV16 (Cervical swab: 15.52%; Urine: 10.91%), and HPV18 (Cervical swab: 5.17%;
297 Urine: 7.27%) (Fig.3A). There were also some coinfection cases, which occupied 12.07% and
298 14.55% of HPV infection cases detected in cervical swabs and urine samples respectively.
299 Most of them were HPV52-HPV Others combination (Cervical swab: 57%; Urine: 50%) (Fig.
300 3B). The proportions of HPV16-HPV Others, HPV18-HPV Others, and HPV16-HPV52-HPV
301 Others in cervical swabs are all equal at 14% while HPV16-HPV Others' proportion (38%) is
302 higher than HPV18-HPV Others (13%) in urine samples. The HPV16-HPV52-HPV Others case
303 detected as HPV16-HPV Others contributed to this difference. A subset of coinfection samples
304 was also confirmed by NGS (Additional File 1: Supplementary Table S1; Supplementary Fig.S3)
305 with HPV31, HPV33, HPV51, HPV56, and HPV58 found, confirming the HPV Others detection
306 by qPCR.
307

308 The pattern of HPV proportion across different age groups by urine and cervical swabs share
309 a considerable similarity (Figure 3C). According to cervical swab samples, HPV Others
310 dominated the HPV type detected, (age group 20-29: 50.00%, age group 30-39: 36%, and age
311 group 40-50: 62.96%). The urine sample also showed an almost identical pattern (age group
312 30-39: 42.86%; age group 40-50: 50%), except for age group 20-29 where HPV Others share
313 the same proportion as HPV52 and coinfection cases at 33%. In the age group of 30-39, HPV52
314 and HPV16 shared a similar proportion with 24.00% and 28.00% in cervical swabs,
315 respectively, and both have 19.05% proportions in urine samples. A small proportion of
316 HPV18 was detected in this group's urine samples (4.76%), while none was found in cervical
317 swabs. This presence of HPV genetic materials has been confirmed with NGS, indicating that
318 the detection of HPV18 was not a false-positive result. In the age group of 40-50, cervical
319 swabs and urine displayed similar proportions of HPV16 (Cervical swab: 7.41%; Urine: 7.14%)
320 and HPV18 (Cervical swab: 11.11%; Urine: 10.71%), while HPV52's proportion was higher in
321 urine samples (21.43%) compared to cervical swabs (11.11%). This minor variation could be
322 attributed to the samples with discordant results between cervical swabs and urine.
323




Figure 3. The HPV proportions of each HPV type/ group found in urine samples were comparable to cervical swabs (A). Urine samples also enable coinfection case detection, resulting in a pattern similar to cervical swabs (B). Generally, the HPV type/group proportions found in urine are similar to cervical swabs, across different age groups. A minor difference, where an HPV18 case found in the urine sample of the 30-39 group was confirmed by NGS (C). Except for the absence of coinfection cases in urine samples from Jakarta, the similarity in the pattern of HPV proportions between urine and cervical swabs was also observed in a location-based analysis (D).

Analyzing the HPV prevalence by location, HPV Others remained dominant, except in Semarang, where it shared the same proportion with coinfection cases (33.33%) as determined by cervical swab (Fig. 3D). Semarang, in fact, had the highest coinfection cases

336 proportion in the urine sample (38.46%) when compared across all locations (Jakarta: 0.00%;
337 Bandung: 13.64%). HPV52 holds the second largest proportion in Jakarta, in both cervical
338 swabs (26.09%) and urine (35.00%), meanwhile, in Semarang, its proportion is the same as
339 HPV16 at 15.38% in urine or lower when using cervical swabs (HPV52: 8.33%; HPV16: 25.00%).
340 Both cervical swabs and urine displayed some small HPV18 proportions in Jakarta (Cervical
341 swabs: 8.7%; Urine: 10%) and Bandung (Cervical swab: 4.35%; Urine: 9.09%), while there were
342 none detected in Semarang. A single coinfection case was found in Jakarta based on cervical
343 swabs (4.35%), while none was detected in urine samples. In Bandung, cervical swabs and
344 urine showed a similar HPV52 proportion (Cervical swabs: 13.04%; Urine: 13.64%) while the
345 HPV16 proportion is higher in the cervical swabs (13.04%) than in urine (9.09%).
346
347
348 **HPV16 and HPV18 genotyping results by hrHPV ReadyMix qPCR Kit is proportional to cobas®**
349 **6800 HPV**
350 To further validate the performance of ReadyMix, we compared the genotyping of HPV16 and
351 HPV18 capability to cobas. The HPV16 proportion out of the positive HPV samples was found
352 to be higher in cervical swabs (ReadyMix: 16.67%; cobas: 19.30%) as compared to urine
353 samples (ReadyMix: 14.29%; cobas: 13.21%) (Fig. 4A, Additional File 1: Supplementary Table
354 S4). The distribution of HPV16 across different age groups is consistent among all samples
355 tested by ReadyMix and cobas with the highest prevalence observed in the age group of 30-
356 39 (Cervical swab ReadyMix: 27.59%, cobas: 32.00%; Urine ReadyMix: 25.00%, cobas:
357 24.00%), followed by the 40-50 age group (Cervical swab ReadyMix: 10.34%, cobas: 12.00%;
358 Urine ReadyMix: 9.68%, cobas: 4.35%) while no HPV16 found in the age group of 20-29 (Fig.
359 4B, Additional File 1: Supplementary Table S4).

360

361 When looking at HPV16 prevalence from the perspective of location origins, cobas detected
362 a higher proportion of HPV16 (46.15%) in cervical swabs samples when compared to results
363 detected by ReadyMix (29.41%) in Semarang (Fig. 4C). The total number of HPV-positive
364 samples detected with cobas were smaller when compared to ReadyMix (ReadyMix: 17 HPV-
365 positives; cobas: 13 HPV-positives) while the HPV16-positive samples detected with both
366 ReadyMix and cobas were similar (ReadyMix: 5 HPV16-positives; cobas: 6 HPV16-positives),
367 resulting in the difference in HPV16 prevalence. On the other hand, the urine samples
368 exhibited a more consistent results with 27.78% and 25.00% of HPV16 proportion when
369 tested with ReadyMix and cobas respectively. Cervical swab samples tested with ReadyMix
370 gave similar proportions of HPV16 in Jakarta (12.50%) and Bandung (12.00%) while a slightly
371 lower HPV16 proportion in Jakarta was obtained when tested using cobas (Jakarta: 9.52%;
372 Bandung: 13.04%). On the other hand, Bandung had a slightly lower HPV16 proportion as
373 compared to Jakarta when urine samples were tested with ReadyMix (Jakarta: 10.00%;
374 Bandung: 8.00%) and cobas (Jakarta: 10.00%; Bandung: 9.52%).

375

376 As for HPV18 prevalence, both tests showed a higher prevalence in urine samples (ReadyMix:
377 7.94%; cobas: 9.43%) when compared to cervical swab samples (ReadyMix: 6.06%; cobas:
378 7.02%) (Fig. 4D). The HPV18 proportion out of the positive HPV samples, in general, was
379 increased with increasing age group, except for the age group 30-39 where no samples tested
380 HPV18 positive (Fig. 4E). The age group of 40-50 had the highest HPV18 positive proportion
381 of 10.34% (ReadyMix) and 16.00% (cobas) on the cervical swab samples and 12.90%
382 (ReadyMix) and 13.04% (cobas) on the urine samples. There were no samples with HPV18
383 tested positive in the 20-29 group.

Location-based HPV positive proportion analysis indicated an agreement between the two tests on the slightly higher HPV18 proportion in Jakarta (ReadyMix: 8.33%; cobas: 9.52%) when compared to Bandung (ReadyMix: 8.00%; cobas: 8.70%) based on cervical swabs (Fig. 4F). On the other hand, urine samples showed a slightly higher HPV18 proportion found in Bandung (ReadyMix: 12.00%; cobas: 14.29%) compared to Jakarta (ReadyMix: 10%; cobas: 10%). There were no samples in Semarang that tested HPV18 positive.




392

393 Figure 4. The pattern of HPV16 proportions among positive cases resulting from ReadyMix was similar
394 to cobas, where cervical swabs had a higher HPV16 proportion compared to urine (A). The similarity
395 was also observed when grouping the subjects into different age (B) and location categories (C). On
396 the other hand, the overall proportion of HPV18 found in urine samples was slightly higher than in
397 cervical swabs, as shown by both ReadyMix and cobas (D). The pattern was also observed when

398 analyzing based on age groups, except for cobas result in age group 40-50 where cervical swab has a
399 slightly higher HPV18 proportion (E). The HPV18 proportion across different locations, as detected by
400 ReadyMix and cobas, remained consistent, even in the presence of a minor pattern discrepancy
401 between cervical swabs and urine samples.
402
403 **DISCUSSION**
404 Our study demonstrates the good performance of the ReadyMix Kit in detecting HPV using
405 both standard cervical swab samples and urine samples, achieving a diagnostic accuracy of
406 99.65% and 98.48% respectively. These final results were also validated by NGS in which the
407 dispute samples were sequenced to confirm the presence of HPV genetic materials. We also
408 validated that the prevalence data of the high-risk HPV using urine samples are similar to
409 those of the cervical swab samples, indicating ReadyMix Kit's reliability in cervical cancer
410 screening.
411
412 The convenience of using urine as a sample for HPV detection has garnered interest as an
413 alternative to the conventional cervical swabbing method. The cervical examination is
414 frequently seen as an uncomfortable and embarrassing procedure, particularly among
415 women in emerging countries, restraining them from getting screened.[18,19] Nishimura et al.
416 (2021) have indicated that self-sampling is more acceptable as it protects privacy and reduces
417 anxiety.[20] Furthermore, Zhao et al. (2022) noted that women showed higher confidence in
418 correctly collecting urine samples rather than cervical samples.[7] Besides, the usage of self-
419 collected urine sample diminishes the need of skilled personnel and special supporting
420 equipment required for cervical swab sample collection.
421

422 Urine samples have been reported to show a promising performance compared to
423 conventional cervical swab samples for the detection of HPV.[9-11] Utilizing first-void urine is
424 crucial to acquire a greater quantity of exfoliated cells, which are likely to have a higher
425 concentration of HPV DNA.[9] In this study, we opted to collect first-void urine at any time of
426 the day for participants' convenience as there was no disparity in HPV DNA concentrations
427 between morning and subsequent urine samples as long as they were obtained within the
428 first-void phase.[21] A comprehensive analysis of multiple studies revealed that the combined
429 sensitivity of high-risk HPV detection in urine samples was 77%, with a specificity of 88%,
430 when compared to cervical samples.[9] We observed a higher sensitivity and specificity at
431 80.88% and 100%, respectively when tested using ReadyMix. The increased value was most
432 likely influenced by NGS confirmation, which verifies initially false-positive results to be true
433 positives. Additionally, ReadyMix exhibited lower rates of invalid results in urine samples
434 compared to cobas. These results highlight the potential of HPV detection in urine by
435 ReadyMix as a reliable screening method.
436
437 ReadyMix's good performance can also be shown in its similar HPV16 and HPV18 genotyping
438 results with cobas. This confirms the proficiency of ReadyMix in accurately determining the
439 HPV16 and HPV18-positive cases, providing clinicians with valuable information to guide
440 subsequent measures. The guideline suggests an additional evaluation such as colposcopy to
441 be performed in HPV16 and HPV18-positive patients, even when cytology results are
442 negative.[22] HPV52 genotyping as an additional genotyping capability of ReadyMix also helps
443 in covering the HPV type with the highest proportion among high-risk HPV detected in
444 Indonesia.[23] Our study found a higher proportion of HPV52 compared to HPV16 and HPV18
445 in both cervical swabs (HPV52: 17.24%; HPV16: 15.52%; HPV18: 5.17%) and urine (HPV52:

446 21.82%; HPV16: 10.91%; HPV18: 7.27%). The result was in line with a previous study where
447 HPV52, HPV16, and HPV18 comprised 23.2%, 18.0%, and 16.1% of the high-risk HPV-positive
448 cases in Indonesia.[23] Despite the 15-year gap, our study's findings continue to emphasize the
449 necessity of a vaccine covering the HPV52 type, in addition to HPV16 and HPV18, for the
450 Indonesian population.
451
452 The screening data by ReadyMix shows an HPV prevalence of 6.28-6.62%, slightly higher than
453 a previous study conducted in Indonesia with a total HPV prevalence of 5.2%, with high-risk
454 HPV contributing to 4.4% prevalence.[24] However, the prevalence is still lower than the
455 worldwide prevalence of high-risk HPV infection which is 10.4%.[25] Unlike most studies where
456 the HPV prevalence decreases with increasing age,[26] we found a lower HPV prevalence in the
457 lowest age group of 20-29 (Cervical swab: 3.82%; Urine: 3.82%) as compared to age group 30-
458 39 (Cervical swab: 7.23%; Urine: 6.07%) and age group 40-50 (Cervical swab: 7.24%; Urine:
459 7.51%). Vet et al. (2008) also observed that there was no decline in HPV prevalence in the
460 subjects of the older age group from Jakarta and Tasikmalaya.[23] Additionally, the increasing
461 prevalence in the older age groups was also found by Yang et al. (2020) in China, resulting in
462 the highest overall HPV prevalence held by age group ≥50 (10.53%), followed by 30-49
463 (8.29%), and the lowest held by age group <30 (7.30%).[27] Several factors that may account for
464 this phenomenon include a lower number of representatives in the young age group caused
465 by the randomized subject screening methodology of this study as well as potentially reduced
466 immunological functions of the older group, making them more susceptible to persistent HPV
467 infection.[27] Based on these data, we suggest an increased effort in the diagnosis of HPV
468 infection in older women as they have a higher risk of cervical cancer progression and lower
469 protection derived from vaccination[28].

470

471 We found HPV prevalence to be the highest in Semarang (Cervical swab: 8.82%; Urine:
472 9.56%), followed by Bandung (Cervical swab: 6.48%; Urine: 6.20%), and lastly Jakarta (Cervical
473 swab 5.97%; Urine: 5.19%). Here we can see that Jakarta, the biggest metropolitan city, had
474 the lowest HPV prevalence as compared to Semarang, a metropolitan city with a larger rural
475 area. Bandung, positioned with a metropolitan rating between the two cities,[29] also exhibits
476 a prevalence value that falls between the prevalence of the two aforementioned cities.
477 Despite many lifestyle factors influencing HPV prevalence in a community,[27] Sabeena et al.
478 (2017) discovered that the infection rate in rural women is higher than in those who lived in
479 urban areas due to lower access to cancer screening and oncology care.[30] This is a continuing
480 problem for emerging countries due to the inequality of access to healthcare services.

481

482 Chaturvedi et al. (2011) found a high proportion of HPV coinfection cases, reaching 43.2%
483 among 2478 HPV-positive women in Costa Rica.[31] The study suggested that multiple α9 types
484 (HPV16, 31, 33, 35, 52, and 58) infections significantly increased the risk of cervical squamous
485 intraepithelial neoplasia (CIN2+) and high-grade squamous intraepithelial lesions (HSIL)
486 compared to a single infection even though there was little evidence of any synergistic effect.
487 In our study, some individuals tested positive for multiple HPV types coinfection with a
488 mixture of HPV16-HPV Others, HPV18-HPV Others, HPV52-HPV Others, and HPV16-HPV52-
489 HPV Others. NGS results also revealed several samples in which multiple HPV Others types
490 were detected (Additional File 1: Supplementary Table 1). Additionally, we found a
491 combination of α9 types within a subset of samples we analyzed using NGS, particularly a
492 combination of HPV16, 52, 31, 33, and HPV58. This result indicated the importance of HPV
493 genotyping as a component of cervical cancer screening.

494

495 Our study to evaluate the usage of urine samples for cervical cancer screening using the hrHPV
496 ReadyMix Kit has several strengths. In addition to having a high number of participants across
497 multiple age groups, we also enrolled subjects from three major cities with varying
498 metropolitan ratings and likely different lifestyles.[29] This is particularly important to ensure
499 that the HPV detection method through urine samples is applicable to the Indonesian
500 population. Our study design also ensured that the paired urine samples and cervical swabs
501 were collected on the same day to reduce the variability of the result that might arise from
502 different sampling times. Additionally, urine samples were verified to be collected before the
503 cervical swab to reduce bias from additional cell debris that might come from the swabbing
504 procedure. We also implemented NGS to confirm the potential false-positive qPCR results to
505 check the presence of HPV in both cervical swabs and urine samples, which resulted in the
506 confirmation of HPV infection that was not detected by cobas. However, the main weakness
507 of our study is that we did not perform any cervical visual inspection to confirm the subject's
508 disease status and its relevance to qPCR results. These limitations should be overcome by
509 future studies to obtain a better perspective of high-risk HPV condition.

510

511 **CONCLUSIONS**

512 The use of hrHPV ReadyMix to detect HPV in urine sample resulted in 98.48% diagnostic
513 accuracy with 80.88% sensitivity and 100% specificity. Furthermore, the genotyping result
514 from urine samples were comparable to cervical swabs. Given the high diagnostic
515 performance, reduction in pain and anxiety during sample collection, and accurate
516 genotyping of the most prevalent HPV types, the implementation of urine sampling combined
517 with hrHPV ReadyMix qPCR Kit appears to be a promising method to overcome the challenges

518 of cervical cancer screening and aid in the facilitation of high-risk HPV surveillance as well as
519 vaccination strategies in many emerging countries, including Indonesia.
520
521 **ABBREVIATIONS**
522 CI: Confidence Interval
523 HPV: Human papillomavirus
524 IC: Internal control
525 IQR: Interquartile range
526 LoD: Limit of detection
527 NGS: Next-generation sequencing
528 NPV: Negative Predictive Value
529 PPV: Positive Predictive Value
530 qPCR: quantitative polymerase chain reaction
531 SD: standard deviation
532 VIA: visual inspection with acetic acid
533
534 **DECLARATIONS**
535 **Ethics approval and consent to participate**
536 The collection of clinical samples, cervical swabs and urine samples, was approved by the
537 Health Research Ethics Committee of the Faculty of Medicine Universitas Indonesia Dr. Cipto
538 Mangunkusumo Hospital under the identifier No. KET- 674 / UN2.F1/ETIK/PPM.00.02/2022.
539 Informed consent was obtained from all participants and all methods were performed in
540 accordance with the Declaration of Helsinki and the approved Indonesian guidelines and
541 regulations for biomedical research.

542

543 **Consent for publication**

544 Not applicable.

545

546 **Availability of data and materials**

547 The datasets supporting the conclusions of this article are included within the article and its

548 supplementary materials.

549

550 **Competing interests**

551 N.S.I., R.U., S.M.K., and M.R.R. are employees of Nusantics, PT Riset Nusantara Genetika. R.U.

552 has financial holdings in Nusantics, PT Riset Nusantara Genetika. N.N. and R.M.S are

553 employees at PT Bio Farma. The remaining authors declare that they have no conflict of

554 interest.

555

556 **Funding**

557 This study was funded by PT Bio Farma in terms of subject recruitment, sample processing,

558 and human resources. PT Bio Farma has a role in the study design, subject recruitment, and

559 decision to submit the paper for publication. The development of the hrHPV ReadyMix kit and

560 the NGS method were funded by Nusantics, PT Riset Nusantara Genetika, which also has a

561 role in the study design, data collection, analysis, interpretation, report writing, and the

562 decision to submit the paper for publication.

563

564 **Author's contribution**

565 R.U., D.W., A., and N.N. designed the study. R.U. designed the test kit. D.W., R.W., and R.M.S.
566 recruited the subjects. N.S.I., D.W., R.W., and R.M.S managed subjects' data. N.S.I., R.U., D.W.,
567 R.W., and I.S.W., analyzed and interpreted the data. N.S.I. and R.W. performed laboratory
568 experiments. S.M.K and M.R.R performed NGS experiments, analyzed, and interpreted NGS
569 data. N.S.I and R.U drafted the first version of the manuscript. N.N and A. provided valuable
570 suggestions to the manuscript. All authors read the manuscript, provided feedback, and
571 approved the submission.

572

573 **Acknowledgements**

574 We want to express our heartfelt thanks to all the dedicated healthcare personnel and
575 participants who made this research possible through their hard work and voluntary sample
576 contributions. Our appreciation extends to Cipto Mangunkusumo National Hospital for
577 providing essential facilities for sample analysis and to Nusantics, PT Riset Nusantara Genetika
578 for providing the ReadyMix kits and their valuable sequencing resources. We are grateful to
579 PT. Bio Farma for their financial support, which greatly assisted in our study. We would like
580 to acknowledge dr. Sri Harsi Teteki, dr. Indriastuti Soetomo, and Dicky Mahardika for their
581 vital role in managing the project. These contributions were crucial in our research, and we
582 are thankful for the collaboration and support that made this study successful.

583

584 **REFERENCES**

585 1 Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé
586 S. Human Papillomavirus and Related Diseases in the World. Barcelona (ES): ICO/IARC

587 Information Centre on HPV and Cancer (HPV Information Centre); 2023 [updated 2023 Mar
588 10; cited 2023 May 4]. Available from: https://hpvcentre.net/statistics/reports/XWX.pdf
589 2 Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national
590 level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021
591 Dec;21(1):1–10.
592 3 Information Centre of HPV and Cancer. Human Papillomavirus and Related Cancers, Fact
593 Sheet 2023 [Internet]. Barcelona (ES): ICO/IARC Information Centre on HPV and Cancer (HPV
594 Information Centre); 2023 [updated 2023 March 10; cited 2023 May 4). Available from:
595 https://hpvcentre.net/statistics/reports/IDN_FS.pdf
596 4 Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical cancer screening: past, present,
597 and future. Sexual Medicine Reviews. 2020 Jan;8(1):28–37.
598 5 Fontham ET, Wolf AM, Church TR, Etzioni R, Flowers CR, Herzig A, Guerra CE, Oeffinger KC,
599 Shih YC–T, Walter LC, Kim JJ. Cervical cancer screening for individuals at average risk: 2020
600 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 2020
601 Sep;70(5):321–46.
602 6 Liu SS, Chan KK, Wei TN, Tse KY, Ngu SF, Chu MM, Lau LS, Cheung AN, Ngan HY. Clinical
603 performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a
604 Chinese population. PLoS One. 2022 Aug 5;17(8):e0272721.
605 7 Zhao S, Huang L, Basu P, Domingo EJ, Supakarapongkul W, Ling WY, Ocviyanti D, Rezhake R,
606 Qiao Y, Tay EH, Zhao F. Cervical cancer burden, status of implementation and challenges of
607 cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries.
608 Cancer Letters. 2022 Jan 28;525:22–32.

609 8 WHO. Cancer Country Profile 2020 [Internet]. Geneva (CH): WHO; 2020 [updated 2020; cited
610 2023 May 8]. Available from: https://cdn.who.int/media/docs/default-source/country-
611 profiles/cancer/idn-2020.pdf?sfvrsn=46ea6569_2&download=true
612 9 Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for
613 presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014 Sep 16;349:g5264
614 10 Choi YS, Jin H, Lee KE. Usefulness Analysis of Urine Samples for Early Screening of Human
615 Papilloma Virus Infection. Journal of Cancer Prevention. 2019 Dec;24(4):240.
616 11 Sargent A, Fletcher S, Bray K, Kitchener HC, Crosbie EJ. Cross-sectional study of HPV testing
617 in self-sampled urine and comparison with matched vaginal and cervical samples in women
618 attending colposcopy for the management of abnormal cervical screening. BMJ Open. 2019
619 Apr 1;9(4):e025388.
620 12 Peng RR, Li HM, Chang H, Li JH, Wang AL, Chen XS. Prevalence and genotype distribution of
621 cervical human papillomavirus infection among female sex workers in Asia: a systematic
622 literature review and meta-analysis. Sexual Health. 2011 Nov 23;9(2):113–9.
623 13 Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible,
624 interactive, scalable and extensible microbiome data science using QIIME 2. Nature
625 biotechnology. 2019 Aug;37(8):852-7.
626 14 Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
627 EMBnet. journal. 2011 May 2;17(1):10-2.
628 15 Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for
629 metagenomics. PeerJ. 2016 Oct 18;4:e2584.
630 16 Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. BLAST+:
631 architecture and applications. BMC bioinformatics. 2009 Dec;10:1-9.

632 17 Cohen J. A coefficient of agreement for nominal scales. Educational and psychological
633 measurement. 1960 Apr;20(1):37-46.
634 18 Robbers GML, Bennett LR, Spagnoletti BRM, Wilopo SA. Facilitators and barriers for the
635 delivery and uptake of cervical cancer screening in Indonesia: a scoping review. Global
636 Health Action. 2021 Jan 1;14(1):1979280.
637 19 Williams-Brennan L, Gastaldo D, Cole DC, Paszat L. Social determinants of health associated
638 with cervical cancer screening among women living in developing countries: a scoping
639 review. Archives of Gynecology and Obstetrics. 2012 Dec;286:1487–505.
640 20 Nishimura H, Yeh PT, Oguntade H, Kennedy CE, Narasimhan M. HPV self-sampling for
641 cervical cancer screening: a systematic review of values and preferences. BMJ Global Health.
642 2021 May 1;6(5):e003743.
643 21 Pattyn J, Van Keer S, Biesmans S, Ieven M, Vanderborght C, Beyers K, Vankerckhoven V,
644 Bruyndonckx R, Van Damme P, Vorsters A. Human papillomavirus detection in urine: Effect
645 of a first-void urine collection device and timing of collection. Journal of Virological Methods.
646 2019 Feb 1;264:23–30.
647 22 Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki
648 A, Nayar R, Saraiya M. 2019 ASCCP risk-based management consensus guidelines for
649 abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital
650 Tract Disease. 2020 Apr;24(2):102.
651 23 Vet JN, De Boer MA, Van den Akker BEWM, Siregar B, Budiningsih S, Tyasmorowati D,
652 Cornain S, Peters AAW, Fleuren GJ. Prevalence of human papillomavirus in Indonesia: a
653 population-based study in three regions. British Journal of Cancer. 2008 Jul;99(1):214–8.
654 24 Handayani S, Dewi RM, Wibowo HA, Dany F, Kipuw NL, Adelina R, Adam K, Yunarto N, Idaiani
655 S, Kristanto AY. Cervical cancer risk factor: HPV infection among Indonesian urban women.

656 In: 4th International Symposium on Health Research (ISHR 2019) 2020 Feb 22 (pp. 452–5).
657 Atlantis Press
658 25 De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide
659 prevalence and genotype distribution of cervical human papillomavirus DNA in women with
660 normal cytology: a meta-analysis. The Lancet Infectious Diseases. 2007 Jul 1;7(7):453–9.
661 26 Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human
662 papillomavirus in females: a global review. Journal of Adolescent Health. 2008 Oct
663 1;43(4):S5–e1.
664 27 Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, Zhao W, Li D, Liu H, Hao M. Prevalence,
665 genotype distribution, and risk factors of cervical HPV infection in Yangqu, China: a
666 population-based survey of 10,086 women. Human Vaccines & Immunotherapeutics. 2020
667 Jul 2;16(7):1645–52.
668 28 Burger EA, Kim JJ, Sy S, Castle PE. Age of acquiring causal human papillomavirus (HPV)
669 infections: leveraging simulation models to explore the natural history of HPV-induced
670 cervical cancer. Clinical Infectious Diseases. 2017 Sep 15;65(6):893–9.
671 29 Demographia. Demographia world urban areas (built-up urban areas or urban
672 agglomerations); 2022 [updated 2023 Aug 31; cited 2023 Jul 17). Available from:
673 http://www.demographia.com/db-worldua.pdf.
674 30 Sabeena S, Bhat PV, Kamath V, Bhat SK, Nair S, Ravishankar N, Chandrabharani K, Arunkumar
675 G. Community-based prevalence of genital human papillomavirus (HPV) infection: a
676 systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention: APJCP.
677 2017;18(1):145.
678 31 Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, Van Doorn LJ,
679 Porras C, Wacholder S, Gonzalez P, Sherman ME. Human papillomavirus infection with

680 multiple types: pattern of coinfection and risk of cervical disease. The Journal of Infectious
681 Diseases. 2011 Apr 1;203(7):910-20.

682

683 **SUPPLEMENTARY INFORMATION**

684 Additional File 1.docx: **Supplementary Fig S1**. Linearity assay of ReadyMix in detecting 14
685 hrHPV types using HPV synthetic DNA as template ranging from 100 to 100,000 GE
686 copies/reaction. A) HPV16; B) HPV18; C) HPV52; D) HPV35; E) HPV31; F) HPV33; G) HPV39; H)
687 HPV45; I) HPV51; J) HPV56; K) HPV58; L) HPV59; M) HPV66; N) HPV68. This assay
688 demonstrated excellent efficiency with a range between 90-110% and $R^2$ ~1. **Supplementary**
689 **Fig S2**. Limit of Detection (LoD) of ReadyMix for each hrHPV target ranging from 10-28
690 copies/20 uL qPCR reaction. **Supplementary Table S1**. The results of NGS run to investigate
691 the presence of hrHPV in the samples based on E6-E7 amplicon sequencing. **Supplementary**
692 **Fig S3**. Stacked taxa bar plot showing the relative abundance of HPV type found in the sample
693 **Supplementary Table S2**. HPV detection using cobas in urine versus cervical swab and NGS.
694 **Supplementary Table S3**. Demographics of the study population. **Supplementary Table S4**.
695 HPV16 and HPV18 proportion within all HPV cases.


A
0
10
20
30
40
ND
Ct Value (HPV)
****
Cervical Swab
Urine
Sample Type
B
0
10
20
30
40
ND
Ct Value (IC)
Cervical Swab
Urine
Sample Type
C
15
20
25
30
35
40
ND
Ct Value
Ct<30
Ct 30-35
Ct>35
Cervical Swab
Urine
Cervical Swab
Urine
Cervical Swab
Urine
Sample Type
D
100
50
0
Sensitivity (%) with 95% CI
94.44
88.89
80.88
Ct<30
Ct<35
Ct<40
Ct Group


A
Prevalence (%) with 95%CI
10
8
6
4
2
0
6.62
6.28
5.94
5.82
Cervical Swab
Urine
Cervical Swab
Urine
Sample Type
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
B
Cervical Swab
Urine
Prevalence (%) with 95%CI
15
10
5
0
3.82
4.46
7.23
6.65
7.24
5.90
3.82
3.18
6.07
6.94
7.51
5.90
20-29
30-39
40-50
20-29
30-39
40-50
Age Group
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
C
Cervical Swab
Urine
Prevalence (%) with 95%CI
15
10
5
0
5.97
5.45
6.48
5.92
8.89
7.35
5.19
5.19
6.20
5.63
9.56
8.09
Jakarta
Bandung
Semarang
Jakarta
Bandung
Semarang
Location
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test


A
Prevalence (%)
10
8
6
4
2
0
Cervical Swab
Urine
Sample Type
HPV16
HPV18
HPV52
HPV Others
Coinfection
B
Coinfection Cases Prevalence (%)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Cervical Swab
Urine
Sample Type
HPV16-HPV52-HPV Others
HPV16-HPV Others
HPV18-HPV Others
HPV52-HPV Others
C
20-29
30-39
40-50
Prevalence (%)
10
8
6
4
2
0
Cervical Swab
Urine
Cervical Swab
Urine
Cervical Swab
Urine
Sample Type
HPV16
HPV18
HPV52
HPV Others
Coinfection
D
Jakarta
Bandung
Semarang
Prevalence (%)
10
8
6
4
2
0
Cervical Swab
Urine
Cervical Swab
Urine
Cervical Swab
Urine
Sample Type
HPV16
HPV18
HPV52
HPV Others
Coinfection


A
HPV16 Proportion (%) with 95%CI
40
30
20
10
0
16.67
14.29
19.30
13.21
Cervical Swab
Urine
Cervical Swab
Urine
Sample Type
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
D
HPV18 Proportion (%) with 95%CI
25
20
15
10
5
0
6.06
7.94
7.02
9.43
Cervical Swab
Urine
Cervical Swab
Urine
Sample Type
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
B
Cervical Swab
Urine
HPV 16 Proportion (%) with 95% CI
80
60
40
20
0
0
0
27.59
32.00
10.34
12.00
0
0
25.00
24.00
9.68
4.35
20-29
30-39
40-50
20-29
30-39
40-50
Age Group
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
E
Cervical Swab
Urine
HPV18 Proportion (%) with 95% CI
50
40
30
20
10
0
0
0
3.45
0
10.34
16.00
0
0
4.17
8.00
12.90
13.04
20-29
30-39
40-50
20-29
30-39
40-50
Age Group
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
C
Cervical Swab
Urine
HPV16 Proportion (%) with 95% CI
80
60
40
20
0
12.50
9.52
12.00
13.04
29.41
46.15
10.00
10.00
8.00
9.52
27.78
25.00
Jakarta
Bandung
Semarang
Jakarta
Bandung
Semarang
Location
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test
F
Cervical Swab
Urine
HPV18 Proportion (%) with 95% CI
50
40
30
20
10
0
8.33
9.52
8.00
8.70
0
0
10.00
10.00
12.00
14.29
0
0
Jakarta
Bandung
Semarang
Jakarta
Bandung
Semarang
Location
PathoScan hrHPV qPCR Kit
FDA-approved HPV DNA test